IN2015DN02577A - - Google Patents
Download PDFInfo
- Publication number
- IN2015DN02577A IN2015DN02577A IN2577DEN2015A IN2015DN02577A IN 2015DN02577 A IN2015DN02577 A IN 2015DN02577A IN 2577DEN2015 A IN2577DEN2015 A IN 2577DEN2015A IN 2015DN02577 A IN2015DN02577 A IN 2015DN02577A
- Authority
- IN
- India
- Prior art keywords
- conjugates
- specific
- maytansines
- peptide
- processes
- Prior art date
Links
- 239000000562 conjugate Substances 0.000 abstract 2
- 102000014914 Carrier Proteins Human genes 0.000 abstract 1
- 239000000611 antibody drug conjugate Substances 0.000 abstract 1
- 229940049595 antibody-drug conjugate Drugs 0.000 abstract 1
- 108091008324 binding proteins Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261717743P | 2012-10-24 | 2012-10-24 | |
| PCT/GB2013/052662 WO2014064424A1 (en) | 2012-10-24 | 2013-10-11 | Drug-protein conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN02577A true IN2015DN02577A (enrdf_load_stackoverflow) | 2015-09-11 |
Family
ID=49488609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2577DEN2015 IN2015DN02577A (enrdf_load_stackoverflow) | 2012-10-24 | 2013-10-11 |
Country Status (19)
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10570151B2 (en) | 2013-03-15 | 2020-02-25 | Regeneron Pharmaceuticals, Inc. | Biologically active molecules, conjugates thereof, and therapeutic uses |
| WO2014194030A2 (en) * | 2013-05-31 | 2014-12-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
| JP6608823B2 (ja) | 2013-08-26 | 2019-11-20 | レゲネロン ファーマシューティカルス，インコーポレーテッド | マクロライドジアステレオマーを含む医薬組成物、その合成方法、及び治療上の使用 |
| EP3145552B1 (en) * | 2014-05-23 | 2020-03-04 | Novartis AG | Methods for making conjugates from disulfide-containing proteins |
| JP6800021B2 (ja) * | 2014-06-02 | 2020-12-16 | レゲネロン ファーマシューティカルス，インコーポレーテッド | 抗体−薬物コンジュゲート、それらの製造、及びそれらの治療用途 |
| GB2531715A (en) * | 2014-10-24 | 2016-05-04 | Polytherics Ltd | Novel drug conjugates |
| SG11201701384XA (en) | 2014-10-14 | 2017-03-30 | Polytherics Ltd | Process for the conjugation of a peptide or protein with a reagent comprising a leaving group including a portion of peg |
| KR102513926B1 (ko) * | 2014-10-24 | 2023-03-23 | 폴리테릭스 리미티드 | 접합체 및 접합 시약 |
| CN107995912A (zh) | 2015-03-27 | 2018-05-04 | 里珍纳龙药品有限公司 | 美登素类衍生物、其偶联物和使用方法 |
| CA2991973C (en) | 2015-07-12 | 2021-12-07 | Suzhou M-Conj Biotech Co., Ltd. | Bridge linkers for conjugation of a cell-binding molecule |
| US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
| EP3331569A1 (en) * | 2015-08-07 | 2018-06-13 | Gamamabs Pharma | Antibodies, antibody drug conjugates and methods of use |
| CA3011440A1 (en) | 2016-01-25 | 2017-08-03 | Regeneron Pharmaceuticals, Inc. | Maytansinoid derivatives, conjugates thereof, and methods of use |
| WO2017161206A1 (en) | 2016-03-16 | 2017-09-21 | Halozyme, Inc. | Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use |
| CN109152845B (zh) | 2016-04-14 | 2022-07-12 | 宝力泰锐克斯有限公司 | 含有在环内包含至少两个(-ch2-ch2-o-)单元的接头的缀合物和缀合试剂 |
| GB201608936D0 (en) | 2016-05-20 | 2016-07-06 | Polytherics Ltd | Novel conjugates and novel conjugating reagents |
| EP4282434A3 (en) | 2016-06-06 | 2024-03-06 | Abzena (UK) Limited | Antibodies, uses thereof and conjugates thereof |
| GB201614162D0 (en) | 2016-08-18 | 2016-10-05 | Polytherics Ltd | Antibodies, uses thereof and conjugates thereof |
| GB201615725D0 (en) * | 2016-09-15 | 2016-11-02 | Polytherics Ltd | Novel cytotoxic agents and conjugates thereof |
| KR20220147719A (ko) | 2016-11-14 | 2022-11-03 | 항저우 디에이씨 바이오테크 씨오, 엘티디 | 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용 |
| US10864279B2 (en) | 2016-12-16 | 2020-12-15 | Industrial Technology Research Institute | Linker-drug and antibody-drug conjugate (ADC) employing the same |
| WO2020081493A1 (en) | 2018-10-16 | 2020-04-23 | Molecular Templates, Inc. | Pd-l1 binding proteins |
| BR112021025984A2 (pt) | 2019-06-29 | 2022-04-12 | Hangzhou Dac Biotech Co Ltd | Conjugado de anticorpo-derivado de tubulisina b (análogo), composto, composição farmacêutica, e, usos do conjugado, dos compostos e das composições farmacêuticas |
| US11918649B2 (en) | 2019-09-18 | 2024-03-05 | Molecular Templates, Inc. | PD-L1-binding molecules comprising Shiga toxin a subunit scaffolds |
| WO2022051591A2 (en) | 2020-09-04 | 2022-03-10 | Novarock Biotherapeutics, Ltd. | Nectin-4 antibodies and uses thereof |
| CA3213295A1 (en) | 2021-03-17 | 2022-09-22 | Molecular Templates, Inc. | Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens |
| WO2022078524A2 (en) | 2021-11-03 | 2022-04-21 | Hangzhou Dac Biotech Co., Ltd. | Specific conjugation of an antibody |
| CN117147824A (zh) * | 2022-05-29 | 2023-12-01 | 菲鹏生物股份有限公司 | 一种抗体缀合物及其应用 |
| CN119161461A (zh) * | 2023-06-19 | 2024-12-20 | 广东菲鹏生物有限公司 | 标记Fab抗体 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0316294D0 (en) | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
| ES2605443T3 (es) * | 2003-11-06 | 2017-03-14 | Seattle Genetics, Inc. | Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia |
| CN101312748A (zh) * | 2005-09-26 | 2008-11-26 | 梅达莱克斯公司 | 抗体-药物轭合物和使用方法 |
| MX2010004219A (es) * | 2007-10-19 | 2010-08-09 | Seattle Genetics Inc | Agentes de enlace de cd19 y usos de los mismos. |
| WO2009134952A2 (en) | 2008-04-30 | 2009-11-05 | Immunogen, Inc | Potent conjugates and hydrophilic linkers |
| WO2010100430A1 (en) | 2009-03-04 | 2010-09-10 | Polytherics Limited | Conjugated proteins and peptides |
| AR078471A1 (es) * | 2009-10-02 | 2011-11-09 | Sanofi Aventis | COMPUESTOS MAITANSINOIDES Y EL USO DE ESTOS PARA PREPARAR CONJUGADOS CON UN ANTICUERPO LOS CUALES SE UTILIZAN COMO AGENTES ANTICANCERIGENOS Y EL PROCEDIMIENTO DE PREPARACIoN DE ESTOS CONJUGADOS |
| RU2015101333A (ru) * | 2012-06-19 | 2016-08-10 | Политерикс Лимитед | Новый способ получения конъюгатов антител и новые конъюгаты антител |
-
2012
- 2012-04-24 NO NO14172620A patent/NO2789793T3/no unknown
-
2013
- 2013-10-11 EP EP13783360.4A patent/EP2911696B1/en active Active
- 2013-10-11 CA CA2884359A patent/CA2884359A1/en not_active Abandoned
- 2013-10-11 CN CN201380055945.7A patent/CN104755106B/zh active Active
- 2013-10-11 DK DK13783360.4T patent/DK2911696T3/en active
- 2013-10-11 WO PCT/GB2013/052662 patent/WO2014064424A1/en active Application Filing
- 2013-10-11 BR BR112015008311A patent/BR112015008311A2/pt not_active Application Discontinuation
- 2013-10-11 ES ES13783360.4T patent/ES2652513T3/es active Active
- 2013-10-11 US US14/437,571 patent/US20150283259A1/en not_active Abandoned
- 2013-10-11 JP JP2015538561A patent/JP6328649B2/ja active Active
- 2013-10-11 MX MX2015005124A patent/MX2015005124A/es unknown
- 2013-10-11 IN IN2577DEN2015 patent/IN2015DN02577A/en unknown
- 2013-10-11 RU RU2015119557A patent/RU2015119557A/ru not_active Application Discontinuation
- 2013-10-11 AU AU2013336410A patent/AU2013336410B2/en active Active
- 2013-10-11 HU HUE13783360A patent/HUE037604T2/hu unknown
- 2013-10-11 SG SG11201501955VA patent/SG11201501955VA/en unknown
- 2013-10-11 KR KR1020157009803A patent/KR20150085808A/ko not_active Withdrawn
-
2015
- 2015-03-11 IL IL237673A patent/IL237673A0/en unknown
- 2015-03-23 ZA ZA2015/01996A patent/ZA201501996B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112015008311A2 (pt) | 2017-07-04 |
| HUE037604T2 (hu) | 2018-09-28 |
| US20150283259A1 (en) | 2015-10-08 |
| AU2013336410B2 (en) | 2017-08-03 |
| RU2015119557A (ru) | 2016-12-20 |
| KR20150085808A (ko) | 2015-07-24 |
| ZA201501996B (en) | 2016-01-27 |
| CN104755106B (zh) | 2018-03-13 |
| WO2014064424A1 (en) | 2014-05-01 |
| CA2884359A1 (en) | 2014-05-01 |
| ES2652513T3 (es) | 2018-02-02 |
| EP2911696B1 (en) | 2017-09-20 |
| MX2015005124A (es) | 2015-10-29 |
| EP2911696A1 (en) | 2015-09-02 |
| JP6328649B2 (ja) | 2018-05-23 |
| DK2911696T3 (en) | 2018-01-08 |
| CN104755106A (zh) | 2015-07-01 |
| NO2789793T3 (enrdf_load_stackoverflow) | 2018-01-27 |
| HK1208186A1 (en) | 2016-02-26 |
| AU2013336410A1 (en) | 2015-04-09 |
| JP2015536329A (ja) | 2015-12-21 |
| IL237673A0 (en) | 2015-04-30 |
| SG11201501955VA (en) | 2015-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2015DN02577A (enrdf_load_stackoverflow) | ||
| NZ703581A (en) | Anti-cd70 antibody drug conjugates | |
| PH12015501000A1 (en) | Anti-notch3 antibodies and antibody-drug conjugates | |
| MY169147A (en) | Drug-protein conjugates | |
| EA201992456A3 (ru) | Самостабилизирующиеся линкерные конъюгаты | |
| WO2013072813A3 (en) | Cytotoxic peptides and antibody drug conjugates thereof | |
| MX2014013807A (es) | Conjugados enlazadores auto-estabilizantes. | |
| MX2019003214A (es) | Formulaciones de proteina de inmunoglobulina del dominio variable dual estable. | |
| GEP20227398B (en) | Novel b7-h3 binding molecules, antibody drug conjugates thereof and usage thereof | |
| PH12013501942A1 (en) | Antibody-drug conjugates | |
| EP3538080A4 (en) | CONJUGATION LINERS, MEDICAMENT-MOLECULE CONJUGATES TO A CELL CONTAINING THE SAME, METHODS OF PREPARING AND USING SUCH CONJUGATES WITH THE BINDERS | |
| NZ737471A (en) | Hydrophilic linkers for conjugation | |
| MX350200B (es) | Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74. | |
| WO2015151080A3 (en) | Specific conjugation of cell-binding molecules | |
| PH12014502406B1 (en) | Anti-il-23p19 antibodies | |
| MX366813B (es) | Polipeptidos de enlace cd3. | |
| PH12018500046A1 (en) | Anti-mesothelin antibodies and immunoconjugates | |
| WO2011142858A3 (en) | Chlorotoxin variants, conjugates, and methods for their use | |
| WO2014018673A3 (en) | Fusion proteins and methods thereof | |
| EP3013789A4 (en) | Amino acid and peptide conjugates and conjugation process | |
| IL272931A (en) | Peptide conjugates, conjugation process and their uses | |
| EP3419962A4 (en) | AMINO ACID AND PEPTIDE CONJUGATES AND CONJUGATION METHOD | |
| SG191060A1 (en) | Robo1-fc fusion protein for use in the treatment of hepatocarcinoma | |
| IL265645A (en) | Monoclonal cmet binding agents, their drug conjugates and uses thereof | |
| EP4331622A3 (en) | Integrin binding peptides and uses thereof |